Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is June 03, 2023.
All times in Eastern Daylight Time.
-
Mountain Valley Pipeline To Proceed
CANONSBURG, Pa.--(BUSINESS WIRE)--On June 3, 2023, the President of the United States signed legislation that raises the Nation's debt limit and ratifies and approves all permits and authorizations... more » -
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced results from a retrospective analysis of the interventional PATHFINDER study. more » -
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL presents data evaluating real-world experience with Galleri® in asymptomatic individuals at ASCO 2023. more » -
Riassunto: La Patient Safety Movement Foundation conclude il suo 10o summit mondiale annuale per la sicurezza dei pazienti, la scienza e la tecnologia
IRVINE, Calif.--(BUSINESS WIRE)--Bill Clinton, 42º presidente degli Stati Uniti, ha presenziato il secondo giorno del 10º Summit mondiale annuale per la sicurezza dei pazienti, la scienza e la tecn... more » -
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer StudyFOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of th... more »
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of th... more » -
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, is continuing its investigation on behalf of SentinelOne, Inc. (“SentinelOne” ... more » -
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earl... more » -
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination w... more » -
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
RAHWAY, N.J.--(BUSINESS WIRE)--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC more » -
A Patient Safety Movement Foundation conclui seu 10o Encontro Anual da Cúpula Mundial de Segurança do Paciente, Ciência e Tecnologia
IRVINE, Califórnia--(BUSINESS WIRE)--Bill Clinton, 42º Presidente dos Estados Unidos, foi destaque no segundo dia do 10º Encontro Anual da Cúpula Mundial de Segurança do Paciente, Ciência e Tecnolo... more »
-
Die Patient Safety Movement Foundation schließt ihren 10. jährlichen Weltgipfel für Patientensicherheit, Wissenschaft und Technologie ab
IRVINE, Kalifornien--(BUSINESS WIRE)--Präsident Bill Clinton, 42. Präsident der Vereinigten Staaten, war der Hauptredner am zweiten Tag des 10. jährlichen Weltgipfels für Patientensicherheit, Wisse... more »
-
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
NEW YORK--(BUSINESS WIRE)--Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with Th... more » -
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalum... more » -
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma more »